Search
droxidopa (Northera, L-DOPS)
Indications:
- orthostatic hypotension associated with Parkinson's disease. multiple-system atrophy, & pure autonomic failure
Dosage:
- start 100 mg TID
- titrate to effect, maximum 1800 mg/day [3]
- capsules
* requires coadministration with L-dopa [2]
Adverse effects:
- boxed warning
- hypertension in the supine position
- headache
- dizziness
- nausea
- hypertension)
- fatigue
Drug interactions:
- iobenguane I 131
- ozanimod
Mechanism of action:
- precursor of noradrenaline
- theres is a deficit of noradrenaline in Parkinson's disease as well as of dopamine
- it has been proposed that this underlies the sudden transient freezing seen usually in advanced disease [PubChem]
Notes:
- some question of drug's efficacy
Interactions
drug adverse effects of adrenergic receptor agonists
General
catecholamine
alpha adrenergic receptor agonist
beta-1 adrenergic receptor agonist
vasoconstrictor agent or vasopressor
Database Correlations
PUBCHEM correlations
References
- Physician's First Watch, Feb 20, 2014
David G. Fairchild, MD, MPH, Editor-in-Chief
Massachusetts Medical Society
http://www.jwatch.org
- FDA News Release: Feb. 18, 2014
FDA approves Northera to treat neurogenic orthostatic
hypotension.
- Medical Knowledge Self Assessment Program (MKSAP) 19.
American College of Physicians, Philadelphia 2021
- RxList: Droxidopa
https://www.rxlist.com/droxidopa/generic-drug.htm